NHS Scotland approves new therapies for actinic keratosis, chronic sialorrhoea and bladder pain syndrome

  • Scottish Medicines Consortium
  • 11 Nov 2019

  • curated by Pavankumar Kamat
  • UK Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

The Scottish Medicines Consortium (SMC) recently published advice pertaining to the acceptance of three new therapies for use by NHS Scotland.

Imiquimod (Zyclara) has been accepted for the topical treatment of immunocompetent adults with clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis of the full face or balding scalp when other topical therapies are contraindicated or less appropriate. Treatment is restricted to patients with large field actinic keratosis (>25cm2). Evidence showed complete clearance of large field actinic keratosis with imiquimod 3.75 per cent cream vs vehicle.

Clostridium botulinum neurotoxin type A (Xeomin) has been accepted for the symptomatic treatment of adults with chronic sialorrhoea due to neurological disorders. Evidence showed that clostridium botulinum neurotoxin type A improved the flow rate of unstimulated saliva and the Global Impression of Change Scale vs placebo.

Pentosan polysulfate sodium (Elmiron) has been accepted for the treatment of bladder pain syndrome in adults experiencing moderate-to-severe pain, urgency and frequency of micturition characterised by either glomerulations or Hunner’s lesions. Evidence showed that pentosan polysulfate sodium significantly improved overall symptoms of bladder pain syndrome vs placebo.